Norris Medicines Peer Comparison

BSE: 524414

₹14.27

₹-0.73 (-4.87%)

As on 01-Sep-2026IST

Market cap

₹14 Cr

Revenue (TTM)

₹8 Cr

P/E Ratio

--

P/B Ratio

-0.9

Div. Yield

0 %

Edit

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	14	21,330	20,606	17,990	17,318
Revenue (₹ Cr)	8	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	-0.37	735.15	678.07	666.92	169.62
Net Margin (%)	-4.82	26.88	28.10	20.60	6.90
RoE (%)	--	19.16	19.73	18.75	20.76
Price to Earnings	--	29.01	30.97	27.94	102.10
Price-To-Book	-0.92	4.84	5.47	4.45	19.15

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	7.60	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	7.62	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	7.12	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	0.48	941.63	796.58	1,139.61	229.86
Depreciation	0.48	57.58	78.10	281.06	17.24
EBIT	0.00	884.05	718.48	858.55	212.62
Interest	0.39	7.69	0.88	190.64	5.72
Other Income	0.02	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	-0.37	992.82	843.56	658.12	228.25
Provision for Tax	0.00	257.67	165.49	-8.80	58.63
Profit after Tax	-0.37	735.15	678.07	666.92	169.62

Liabilities (₹ Cr)

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	-15.15	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	18.51	91.50	28.74	1,392.75	134.50
Current Liabilities	9.53	627.48	385.94	2,077.10	981.81
Total Liabilities	13.81	4,911.11	3,207.85	6,862.28	1,879.19

Assets (₹ Cr)

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	4.90	770.28	1,291.22	5,617.77	42.47
Current Assets	5.81	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	13.81	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	21.58	2.50	0.55	2,421.66	0.00
Net Current Assets	-3.71	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	1.33	363.79	0.64	64.29	98.41

Cashflow (₹ Cr)

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	0.51	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	0.00	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-0.50	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	0.00	383.07	59.32	103.72	30.57

Ratios

Profitability Ratios

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	-10.11	26.21	26.22	13.59	21.29
ROE (%)	0.00	19.16	19.73	18.75	20.76
ROA (%)	-2.75	14.95	18.69	9.26	9.67
EBIT Margin (%)	-0.01	34.40	31.41	26.58	8.74
Net Margin (%)	-4.82	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	16.00	10.69	15.01	9.59	31.10
EBIT Growth (%)	99.86	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	69.00	-9.09	19.61	62.68	-7.49
EPS Growth (%)	69.00	14.40	17.73	67.41	-18.33
Book Value Growth (%)	-9.08	17.30	23.77	10.19	7.70

Valuation Ratios

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	-38.89	27.65	30.97	27.26	99.79
Price / Book Value	-0.92	4.84	5.47	4.45	19.15
Dividend Yield (%)	0.00	1.61	0.15	0.56	0.52
EV/EBITDA	74.14	19.35	24.74	17.71	73.39
Market Cap (₹ Cr)	16.66	18,318.10	15,219.80	19,292.77	21,515.93

Solvency Ratios

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	-1.22	0.00	0.00	0.24	0.00
Short term debt to equity ratio	-0.21	0.00	0.00	0.14	--
Current Ratio	0.61	6.06	6.70	0.74	1.77
Quick Ratio	0.19	5.31	5.59	0.53	0.73
Interest Coverage	0.05	130.11	959.59	4.45	40.90

Operating Efficiency Ratios

	Norris Medicines	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	15.45	7.07	36.10	21.07	8.79
Asset Turnover	0.57	0.52	0.63	0.45	1.39
Receivable days	77.44	29.10	110.70	54.07	35.81
Inventory Days	265.33	69.53	65.86	32.16	82.25
Payable days	229.77	76.77	105.88	140.91	124.39
Cash Conversion Cycle	113.00	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly